Manufacturer
Veritaz Healthcare Ltd.
Contents
Zidovudine
Indication
HIV infection
Instruction
May be taken with or without food.
Drug interaction
Decreased plasma concentration w/ rifampicin resulting in partial or total loss of efficacy of zidovudine. Increased risk of anaemia w/ ribavirin in patients co-infected w/ HCV. Antagonistic effect w/ stavudine or doxorubicn. Increased plasma level w/ probenecid, atovaquone, valproic acid, fluconazole, or methadone. May alter phenytoin blood levels. Increased adverse effect w/ potentially nephrotoxic or myelosuppressive drugs (e.g. systemic pentamidine, dapsone, pyrimethamine, co-trimoxazole, amphotericin, flucytosine, ganciclovir, interferon, vincristine, vinblastine, doxorubicin). Reduced absorption w/ clarithromycin.Potentially Fatal: Risk of hepatic decompensation when used concomitantly w/ interferon alfa (w/ or w/o ribavirin) in HIV and HBV/HCV co-infected patients.
Malaysia
